Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Virus Diseases AND H1N1 Influenza Virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Virus Diseases AND H1N1 Influenza Virus. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-001974-27 Sponsor Protocol Number: STOPFLU Start Date*: 2019-10-15
    Sponsor Name:Centre Hospitalier Universitaire Vaudois (CHUV)
    Full Title: Reducing the Burden of Influenza after Solid-Organ Transplantation: the STOP-FLU trial [Swiss Trial in solid Organ transplantation on Prevention of inFLUenza]
    Medical condition: Influenza in solid organ transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    21.1 10042613 - Surgical and medical procedures 10061890 Organ transplant PT
    21.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001857-29 Sponsor Protocol Number: V130_14 Start Date*: 2019-03-13
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to...
    Medical condition: Prophylaxis of influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005183-15 Sponsor Protocol Number: CSLCT-CAL-09-60 Start Date*: 2015-01-09
    Sponsor Name:CSL Limited
    Full Title: A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months ...
    Medical condition: Influenza, human.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000176-10 Sponsor Protocol Number: CSLCT-CAL-09-62 Start Date*: 2015-03-23
    Sponsor Name:CSL Limited
    Full Title: A Phase II, Multicenter, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL’s 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pedi...
    Medical condition: Influenza, human.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001008-49 Sponsor Protocol Number: NV22155 Start Date*: 2016-09-30
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002599-95 Sponsor Protocol Number: V118_05E1 Start Date*: 2014-09-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Admin...
    Medical condition: Prophylaxis for influenza virus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013326-17 Sponsor Protocol Number: MI-CP208 Start Date*: 2013-05-20
    Sponsor Name:MedImmune, LLC
    Full Title: A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children
    Medical condition: Prophylaxis of influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002080-26 Sponsor Protocol Number: V58P15 Start Date*: 2013-08-28
    Sponsor Name:Novartis Vaccines & Diagnostics AG
    Full Title: A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (tivc) or in Embryonated Eggs (TI...
    Medical condition: volunteers at high risk for influenza-related complications (protection against influenza)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10016794 Flu vaccination LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004753-33 Sponsor Protocol Number: CSLCT-QIV-15-03 Start Date*: 2016-12-15
    Sponsor Name:Seqirus GmbH
    Full Title: A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with a US-li...
    Medical condition: Prophylaxis for influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004133-25 Sponsor Protocol Number: CSLCT-QIV-13-02 Start Date*: 2016-12-15
    Sponsor Name:Seqirus GmbH
    Full Title: A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with...
    Medical condition: Prophylaxis for influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005558-63 Sponsor Protocol Number: V70P3 Start Date*: 2006-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nona...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000955-10 Sponsor Protocol Number: 201251 Start Date*: 2014-08-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double-blind, randomized, multicenter study to assess safety and immunogenicity of GlaxoSmithKline Biologicals’ Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) manufactured w...
    Medical condition: Healthy volunteers (Active immunization of adults and children against influenza)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10059430 Influenza immunization LLT
    17.1 100000004862 10022002 Influenza A virus infection LLT
    17.1 100000004862 10022003 Influenza B virus infection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-000218-12 Sponsor Protocol Number: V118_05 Start Date*: 2013-09-17
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus...
    Medical condition: Prophylaxis for influenza virus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-000576-19 Sponsor Protocol Number: VAP00026 Start Date*: 2022-07-29
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared with Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000881-12 Sponsor Protocol Number: M13-998 Start Date*: 2013-07-11
    Sponsor Name:Abbott Biologicals B.V
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2013/2014. An Open-Label, Baseline- Controlled Study in Two Age Gro...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016226-13 Sponsor Protocol Number: ANRS 151 Start Date*: 2009-10-15
    Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales
    Full Title: Etude de phase II randomisée évaluant l'immunogénicité et la tolérance du vaccin antigrippal A(H1N1)v adjuvanté comparativement au vaccin antigrippal A(H1N1)v non adjuvanté chez des patients infect...
    Medical condition: infection VIH et vaccination anti-grippe A (H1N1)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10016794 Flu vaccination LLT
    12.0 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001032-57 Sponsor Protocol Number: M13-567 Start Date*: 2012-06-26
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2012/2013. An Open-Label, Baseline- Controlled Study in Two Age ...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003512-23 Sponsor Protocol Number: 114495 Start Date*: 2015-06-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, observer blind, multicenter study to evaluate the safety and immunogenicity of a single low dose of AS03-adjuvanted, Quebec- or Dresden- manufactured monovalent A/California...
    Medical condition: Healthy volunteers (immunization against A/California/7/2009 (H1N1)v-like influenza)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10073988 Bird flu LLT
    18.0 100000004865 10021433 Immunization LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001094-25 Sponsor Protocol Number: 200188 Start Date*: 2013-07-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open-label, non-randomised, multi-centre, single dose study to assess the immunogenicity and safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Influs...
    Medical condition: Immunization of healthy adults against influenza
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10059430 Influenza immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023815-33 Sponsor Protocol Number: GHB_CSP_CL_00008_03 Start Date*: 2011-01-05
    Sponsor Name:AVIR Green Hills Biotechnology Research Development Trade AG
    Full Title: Randomised, double-blind, placebo-controlled, phase I/II study of single dose GHB16L2 trivalent influenza vaccine in healthy adults
    Medical condition: The intended indication for the IMP GHB16L2 is prevention of influenza A (H1N1, H3N2) and B contained in the vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 13:03:31 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA